Shield ended the year with cash of £4.1mln, down from £9.8mln at the end of 2018. Following the receipt in January of the US$11.4mln upfront payment from ASK Pharm (its China partner), the group's cash runway now extends into 2021.
Full interview: Shield Therapeutics 'seeking to conclude US partnering discussions'
Quick facts: Shield Therapeutics PLC
Price: 83.5 GBX
Market Cap: £97.85 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE